Second Circuit declines to hear appeal in Aggrenox reverse-payment case
( September 16, 2015, 22:45 GMT | Official Statement) -- MLex Summary: The US Court of Appeals for the Second Circuit has denied an interlocutory appeal by Barr Pharmaceuticals and other defendants accused of illegally delaying generic entry of the drug Aggrenox. US District Judge Stefan R. Underhill certified the issue for an appeal, saying more guidance from the appeals court on the substantive standard to apply to reverse-payment cases would be useful. "We appreciate that appellate elucidation of an applicable standard in advance of trial might assist in limiting the duration of a trial in a complex matter," the court said. "Nevertheless, we think the better practice, especially in an emerging area of the law such as antitrust challenges to reverse payment settlements, is to leave it to the parties in the first instance to present the evidence they believe is needed to prove and counter the claim of unlawfulness."Docket entry follows below....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.